. Author manuscript; available in PMC: 2019 Jun 1.

Published in final edited form as: Biol Blood Marrow Transplant. 2017 Dec 11;24(6):1163–1171. doi: 10.1016/j.bbmt.2017.12.771

Table 4.

Univariate comparison of overall survival between non-HCT and auto-HCT cohort patients receiving transplantation within 1 year of early therapy failure.

Outcomes	Non-HCT cohort (NLCS Dataset)		Auto-HCT within 1year of ETF cohort (CIBMTR Dataset)		FDR Adjusted p-value*
Outcomes	N Eval	Prob (95% CI)	N Eval	Prob (95% CI)	FDR Adjusted p-value*
Overall survival	174		123

1-year		84 (78–89)%		90 (85–94)%	0.12

2-year		76 (69–82)%		84 (79–90)%	0.011

3-year		70 (63–77)%		80 (74–87)%	0.08

5-year		60 (52–67)%		73 (66–81)%	0.05

Abbreviations: ETF=early therapy failure; N Eval=number evaluable, Prob=probability.